Santaris Pharma Overview
- Year Founded
-
2003
- Status
-
Acquired/Merged
- Employees
-
1
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$450M
Santaris Pharma General Information
Description
Developer of ribonucleic acid (RNA) targeted therapies. The company's Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine is designed to deliver single-stranded Locked Nucleic Acid (LNA) based drug candidates across an array of disease states, including cancer, cardiovascular disease, infectious and inflammatory diseases and rare genetic disorders.
Contact Information
Website
www.santaris.comCorporate Office
- Fremtidsvej 3
- 2970 Horsholm
- Denmark
Corporate Office
- Fremtidsvej 3
- 2970 Horsholm
- Denmark
Santaris Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 31-Aug-2014 | $450M | Completed | Generating Revenue | ||
| 5. Later Stage VC | 20-Jun-2012 | Completed | Generating Revenue | |||
| 4. Grant | 15-May-2008 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 18-Dec-2007 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 15-Mar-2006 | $53.7M | $59.1M | Completed | Generating Revenue | |
| 1. Early Stage VC | 29-Jun-2005 | $5.35M | $5.35M | Completed | Product Development |
Santaris Pharma Signals
Santaris Pharma Former Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BankInvest Biotech Ventures | Venture Capital | Minority | ||
| DKA Capital | PE/Buyout | Minority | ||
| Dansk Erhvervsinvestering | Venture Capital | Minority | ||
| Forbion | Venture Capital | Minority | ||
| Gilde Healthcare | PE/Buyout | Minority |
Santaris Pharma Investments (1)
Santaris Pharma’s most recent deal was a Corporate Asset Purchase with RNA teknologi. The deal was made on 01-Jan-2007.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| RNA teknologi | 01-Jan-2007 | Corporate Asset Purchase | Buildings and Property |
Santaris Pharma FAQs
-
When was Santaris Pharma founded?
Santaris Pharma was founded in 2003.
-
Where is Santaris Pharma headquartered?
Santaris Pharma is headquartered in Horsholm, Denmark.
-
What is the size of Santaris Pharma?
Santaris Pharma has 1 total employees.
-
What industry is Santaris Pharma in?
Santaris Pharma’s primary industry is Drug Discovery.
-
Is Santaris Pharma a private or public company?
Santaris Pharma is a Private company.
-
What is the current valuation of Santaris Pharma?
The current valuation of Santaris Pharma is .
-
What is Santaris Pharma’s current revenue?
The current revenue for Santaris Pharma is .
-
How much funding has Santaris Pharma raised over time?
Santaris Pharma has raised $100M.
-
Who are Santaris Pharma’s investors?
BankInvest Biotech Ventures, DKA Capital, Dansk Erhvervsinvestering, Forbion, and Gilde Healthcare are 5 of 16 investors who have invested in Santaris Pharma.
-
When was Santaris Pharma acquired?
Santaris Pharma was acquired on 31-Aug-2014.
-
Who acquired Santaris Pharma?
Santaris Pharma was acquired by Roche.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process